NASDAQ:CASI CASI Pharmaceuticals 5/16/2025 Earnings Report $1.89 0.00 (0.00%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast CASI Pharmaceuticals EPS ResultsActual EPS-$0.69Consensus EPS -$0.61Beat/MissMissed by -$0.08One Year Ago EPSN/ACASI Pharmaceuticals Revenue ResultsActual Revenue$6.24 millionExpected Revenue$7.39 millionBeat/MissMissed by -$1.15 millionYoY Revenue GrowthN/ACASI Pharmaceuticals Announcement DetailsQuarterDate5/16/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsCASI Pharmaceuticals' next earnings date is estimated for Friday, August 15, 2025, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile CASI Pharmaceuticals Earnings HeadlinesCASI Pharmaceuticals (NASDAQ:CASI) Now Covered by Wall Street ZenMay 23, 2025 | americanbankingnews.comHC Wainwright Issues Positive Outlook for CASI EarningsMay 23, 2025 | americanbankingnews.comOnly a handful of people know the setup that's defied these chaotic markets.Since February, we've hit 28 out of 29 trades – that's a 96% win rate taking simple options setups on one single ticker every day. That's why Jack Carter and I teamed up to reveal The 4PM Payout Plan. Our goal here was to show you how to take these daily setups every morning to collect a 4PM payout. Naturally, no one can guarantee what the market does in the future… But these simple daily options setups have paid out with the market rallying, dropping, or staying flat. And if you want to be one of the few to not just know the ropes behind these daily setups but also deploy them for yourself…May 29, 2025 | WealthPress (Ad)HC Wainwright Reaffirms Buy Rating for CASI Pharmaceuticals (NASDAQ:CASI)May 21, 2025 | americanbankingnews.comCASI Pharmaceuticals to divest Chinese assets in $20 million dealMay 12, 2025 | msn.comCasi Pharmaceuticals price target lowered to $4 from $6 at H.C. WainwrightApril 10, 2025 | markets.businessinsider.comSee More CASI Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CASI Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CASI Pharmaceuticals and other key companies, straight to your email. Email Address About CASI PharmaceuticalsCASI Pharmaceuticals (NASDAQ:CASI), a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.View CASI Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles CrowdStrike Stock Slips: Analyst Downgrades Before Earnings Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns?Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Upcoming Earnings CrowdStrike (6/3/2025)Haleon (6/4/2025)Broadcom (6/5/2025)Oracle (6/10/2025)Adobe (6/12/2025)Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
